The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
[Journal of Parkinson’s Disease, 9(3) (2019), 553–563, DOI 10.3233/JPD-191648]
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd191648
On page 560, the following Disclaimer was missing from the published article:
The findings and conclusions in this publications by the authors from US Food and Drug Administration are those of the authors and do not necessarily represent the views of the FDA.
